{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:47Z","timestamp":1792787867155,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M772209"],"award-info":[{"award-number":["2025M772209"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Explorers Program of Shanghai","award":["25TS1403800"],"award-info":[{"award-number":["25TS1403800"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373358"],"award-info":[{"award-number":["82373358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Higher Education Society Research Project","award":["2QYB24089"],"award-info":[{"award-number":["2QYB24089"]}]},{"name":"Shanghai Municipal Education Commission Grant Support","award":["2023ZKZD23"],"award-info":[{"award-number":["2023ZKZD23"]}],"id":[{"id":"https:\/\/ror.org\/05tewj457","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ren Ji Hospital","award":["LYZXHXKT220845"],"award-info":[{"award-number":["LYZXHXKT220845"]}]},{"DOI":"10.13039\/501100020737","name":"Renji Hospital","doi-asserted-by":"publisher","award":["RJLJHZ-02"],"award-info":[{"award-number":["RJLJHZ-02"]}],"id":[{"id":"10.13039\/501100020737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A subset of hormone-sensitive prostate cancer (HSPC) exhibits low prostate-specific membrane antigen (PSMA) uptake on PET imaging, which may limit the performance of PSMA-based detection and PSMA-directed therapeutic strategies. However, the clinical features and molecular basis of HSPC with low PSMA expression remain incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We first analyzed a retrospective dual-tracer PET cohort to estimate the frequency and clinical characteristics of tumors with low PSMA uptake at initial diagnosis. We then collected radical prostatectomy specimens for proteomics profiling, classifying tumors as low-PSMA (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200916) or high-PSMA (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200919) based on concordant [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 PET and PSMA immunohistochemistry, with adjacent benign tissues included as controls. Label-free quantitative proteomics and integrative bioinformatic analyses were used to characterize low-PSMA\u2013associated protein features and nominate candidate cell-surface membrane targets, followed by validation using RT-qPCR and immunohistochemistry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Low-PSMA HSPC was identified in 7.23% (122\/1,688) of patients in the retrospective dual-tracer PET cohort, indicating that reduced PSMA uptake is already observable at initial diagnosis. Although these tumors showed reduced PSMA expression, they were not uniformly low-risk, with 42.62% of cases exhibiting Gleason score\u2009\u2265\u20098. In the proteomic cohort, low-PSMA tumors showed concordant reductions in PSMA uptake and protein expression, supporting imaging\u2013pathology alignment. Proteomic analysis revealed a distinct molecular state characterized by enrichment of tissue remodeling, repair, epithelial organization, and microenvironment-related programs, together with attenuation of androgen-response, E2F, and MYC-associated proliferative signaling. Cell-surface membrane surface target prioritization identified ALCAM and TACSTD2 as candidates, among which ALCAM was consistently upregulated in low-PSMA tumors at both mRNA and protein levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HSPC with low PSMA expression represents a distinct clinical and molecular state rather than a simple low-risk subgroup. Its proteomic features suggest altered epithelial differentiation, tissue remodeling, and reduced canonical prostate cancer signaling. ALCAM may serve as a complementary membrane biomarker for improving the molecular recognition of low-PSMA HSPC and supporting future alternative imaging or targeting strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-026-01546-w","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:14:57Z","timestamp":1783044897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-PSMA hormone-sensitive prostate cancer: a distinct clinical and molecular state"],"prefix":"10.1186","volume":"32","author":[{"given":"Haotian","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruopeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"6","key":"1546_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2967\/jnumed.122.264981","volume":"64","author":"V Al Jalali","year":"2023","unstructured":"Al Jalali V, Wasinger G, Rasul S, Grubm\u00fcller B, Wulkersdorfer B, Balber T, et al. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Na\u00efve Prostate Cancer. J Nucl Med. 2023;64(6):863\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.264981.","journal-title":"J Nucl Med"},{"issue":"6","key":"1546_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.eururo.2024.09.033","volume":"86","author":"MK Bakht","year":"2024","unstructured":"Bakht MK, Beltran H. Aiming high: prostate-specific membrane antigen expression in treatment-na\u00efve prostate cancer. Eur Urol. 2024;86(6):588\u201390. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.033.","journal-title":"Eur Urol"},{"issue":"2","key":"1546_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","volume":"26","author":"MK Bakht","year":"2018","unstructured":"Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018;26(2):131\u201346. https:\/\/doi.org\/10.1530\/ERC-18-0226. PubMed PMID: 30400059.","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"1546_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699\u2013715. https:\/\/doi.org\/10.1038\/s43018-023-00539-6.","journal-title":"Nat Cancer"},{"issue":"4","key":"1546_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121314","volume":"10","author":"D Bausch-Fluck","year":"2015","unstructured":"Bausch-Fluck D, Hofmann A, Bock T, Frei AP, Cerciello F, Jacobs A, et al. A Mass Spectrometric-Derived Cell Surface Protein Atlas. PLoS ONE. 2015;10(4):e0121314. https:\/\/doi.org\/10.1371\/journal.pone.0121314.","journal-title":"PLoS ONE"},{"issue":"3","key":"1546_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834. PubMed PMID: 38572751.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1546_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.120.262250","volume":"63","author":"R Chen","year":"2022","unstructured":"Chen R, Wang Y, Zhu Y, Shi Y, Xu L, Huang G, et al. The Added Value of 18F-FDG PET\/CT Compared with 68Ga-PSMA PET\/CT in Patients with Castration-Resistant Prostate Cancer. J Nucl Med. 2022;63(1):69\u201375. https:\/\/doi.org\/10.2967\/jnumed.120.262250. PubMedPMID:34980667; PubMedCentralPMCID: PMC8717199.","journal-title":"J Nucl Med"},{"key":"1546_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07646-9","author":"R Chen","year":"2025","unstructured":"Chen R, Wang Y, Chen Q, Dong L, Huang G, Liu J. Dual-tracer PET\/CT identifies an aggressive PSMA-negative\/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07646-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1546_CR9","doi-asserted-by":"publisher","unstructured":"Chen R, Wang Y, Dong L, Zhao H, Li L, Huang G, et al. A dual-tracer approach for enhanced nodal staging in prostate cancer: the role of [18F]FDG PET\/CT for detecting [68\u00a0Ga]Ga-PSMA-11-negative metastases. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07683-4","DOI":"10.1007\/s00259-025-07683-4"},{"issue":"4","key":"1546_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016;30(4):563\u201377. https:\/\/doi.org\/10.1016\/j.ccell.2016.09.005. PubMedPMID: 27728805; PubMedCentralPMCID: PMC5540451.","journal-title":"Cancer Cell"},{"issue":"11","key":"1546_CR11","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/pros.24549","volume":"83","author":"T Derlin","year":"2023","unstructured":"Derlin T, Riethdorf S, Schumacher U, Lafos M, Peine S, Coith C, et al. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. Prostate. 2023;83(11):1076\u201388. https:\/\/doi.org\/10.1002\/pros.24549. PubMed PMID: 37147881.","journal-title":"Prostate"},{"issue":"9","key":"1546_CR12","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s43018-024-00820-2","volume":"5","author":"B Dong","year":"2024","unstructured":"Dong B, Xu JY, Huang Y, Guo J, Dong Q, Wang Y, et al. Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers. Nat Cancer. 2024;5(9):1427\u201347. https:\/\/doi.org\/10.1038\/s43018-024-00820-2.","journal-title":"Nat Cancer"},{"issue":"3","key":"1546_CR13","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/RLU.0000000000005064","volume":"49","author":"N Erg\u00fcl","year":"2024","unstructured":"Erg\u00fcl N, \u00c7ermik TF, Al\u00e7\u0131n G, Arslan E, Erol Fenercio\u011flu \u00d6, Beyhan E, et al. Contribution of 68Ga-DOTA-FAPI-04 PET\/CT to prostate cancer imaging: complementary role in PSMA-negative cases. Clin Nucl Med. 2024;49(3):e105\u201310. https:\/\/doi.org\/10.1097\/RLU.0000000000005064.","journal-title":"Clin Nucl Med"},{"key":"1546_CR15","doi-asserted-by":"publisher","unstructured":"Ferraro DA, R\u00fcschoff JH, Muehlematter UJ, Kranzb\u00fchler B, M\u00fcller J, Messerli M, et al. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET. Theranostics. 2020;10(14):6082\u201394. https:\/\/doi.org\/10.7150\/thno.44584","DOI":"10.7150\/thno.44584"},{"issue":"21","key":"1546_CR16","doi-asserted-by":"publisher","first-page":"14623","DOI":"10.1021\/acs.jmedchem.3c01135","volume":"66","author":"Q Gan","year":"2023","unstructured":"Gan Q, Cui K, Cao Q, Zhang N, Yang MF, Yang X. Development of a 18F-Labeled Bicyclic Peptide Targeting EphA2 for Molecular Imaging of PSMA-Negative Prostate Cancer. J Med Chem. 2023;66(21):14623\u201332. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01135.","journal-title":"J Med Chem"},{"key":"1546_CR17","doi-asserted-by":"publisher","unstructured":"Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, et al. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Reports. 2022;39(1). https:\/\/doi.org\/10.1016\/j.celrep.2022.110595 PubMed PMID: 35385726.","DOI":"10.1016\/j.celrep.2022.110595"},{"issue":"5","key":"1546_CR18","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/0008-5472.CAN-13-1296","volume":"74","author":"AG Hansen","year":"2014","unstructured":"Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, et al. ALCAM\/CD166 is a TGF-\u03b2-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res. 2014;74(5):1404\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1296. PubMedPMID:24385212; PubMedCentralPMCID: PMC4149913.","journal-title":"Cancer Res"},{"issue":"3","key":"1546_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/modpathol.3800054","volume":"17","author":"PA Humphrey","year":"2004","unstructured":"Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004;17(3):292\u2013306. https:\/\/doi.org\/10.1038\/modpathol.3800054. PubMed PMID: 14976540.","journal-title":"Mod Pathol"},{"issue":"7","key":"1546_CR20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2967\/jnumed.123.267107","volume":"65","author":"C Imberti","year":"2024","unstructured":"Imberti C, De Gregorio R, Korsen JA, Hoang TT, Khitrov S, Kalidindi T, et al. CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer. J Nucl Med. 2024;65(7):1043\u201350. https:\/\/doi.org\/10.2967\/jnumed.123.267107.","journal-title":"J Nucl Med"},{"issue":"4","key":"1546_CR21","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41391-024-00930-z","volume":"28","author":"RB Incesu","year":"2025","unstructured":"Incesu RB, Preisser F, Nohe F, Maurer T, Graefen M, Tilki D. Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer. Prostate Cancer Prostatic Dis. 2025;28(4):874\u20138. https:\/\/doi.org\/10.1038\/s41391-024-00930-z. PubMed PMID: 39762549; PubMed Central PMCID: PMC12643919.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"1546_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","volume":"54","author":"MR Jochumsen","year":"2024","unstructured":"Jochumsen MR, Bouchelouche K. PSMA PET\/CT for primary staging of prostate cancer - an updated overview. Semin Nucl Med. 2024;54(1):39\u201345. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.001. Prostate cancer.","journal-title":"Semin Nucl Med"},{"key":"1546_CR23","unstructured":"Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59(3):241\u201368. PubMed PMID: 26213140; PubMed Central PMCID: PMC4859214."},{"issue":"1","key":"1546_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s43856-026-01444-6","volume":"6","author":"A Li","year":"2026","unstructured":"Li A, Wu H, Zhou X, Zhu Y, Zhang W, Shen K, et al. Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer. Commun Med (Lond). 2026;6(1):164. https:\/\/doi.org\/10.1038\/s43856-026-01444-6. PubMedPMID:41703276; PubMedCentralPMCID: PMC13022180.","journal-title":"Commun Med (Lond)"},{"issue":"15","key":"1546_CR25","doi-asserted-by":"publisher","first-page":"23902","DOI":"10.1038\/s41598-025-06393-z","volume":"4","author":"Y Mulati","year":"2025","unstructured":"Mulati Y, Shen Q, Tian Y, Chen Y, Yao K, Yu W, et al. Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases. Sci Rep. 2025;4(15):23902. https:\/\/doi.org\/10.1038\/s41598-025-06393-z. PubMed PMID: 40615466.","journal-title":"Sci Rep"},{"issue":"6","key":"1546_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/pros.70124","volume":"86","author":"A Ozen","year":"2026","unstructured":"Ozen A, Sarikaya Z, Gur C, Ozboru D, Canat HL. Pelvic Lymph Node Staging With PSMA PET in Prostate Cancer: Surgical Validation With Implications for Radiotherapy Planning. Prostate. 2026;86(6):648\u201354. https:\/\/doi.org\/10.1002\/pros.70124. PubMed PMID: 41570172.","journal-title":"Prostate"},{"issue":"6","key":"1546_CR27","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s00259-023-06123-5","volume":"50","author":"J Pan","year":"2023","unstructured":"Pan J, Zhao J, Ni X, Zhu B, Hu X, Wang Q, et al. Heterogeneity of [68Ga]Ga-PSMA-11 PET\/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response. Eur J Nucl Med Mol Imaging. 2023;50(6):1822\u201332. https:\/\/doi.org\/10.1007\/s00259-023-06123-5. PubMed PMID: 36719427.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10162","key":"1546_CR28","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3. PubMedPMID:30355464; PubMedCentralPMCID:PMC6269599.","journal-title":"Lancet"},{"issue":"4","key":"1546_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. Eur Urol. 2019;76(4):469\u201378. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030. PubMedPMID:31345636; PubMedCentralPMCID: PMC6853166.","journal-title":"Eur Urol"},{"key":"1546_CR30","doi-asserted-by":"publisher","unstructured":"Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019 Mar 20;11(484):eaav0891. https:\/\/doi.org\/10.1126\/scitranslmed.aav0891 PubMed PMID: 30894499; PubMed Central PMCID: PMC6525633.","DOI":"10.1126\/scitranslmed.aav0891"},{"issue":"5","key":"1546_CR31","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.stem.2012.03.009","volume":"10","author":"J Qin","year":"2012","unstructured":"Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, et al. The PSA\u2212\/lo Prostate Cancer Cell Population Harbors Self-Renewing Long-Term Tumor-Propagating Cells that Resist Castration. Cell Stem Cell. 2012;10(5):556\u201369. https:\/\/doi.org\/10.1016\/j.stem.2012.03.009. PubMed PMID: 22560078.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"1546_CR32","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2214\/AJR.19.21894","volume":"214","author":"MS Robertson","year":"2020","unstructured":"Robertson MS, Sakellis CG, Hyun H, Jacene HA. Extraprostatic uptake of18 F-fluciclovine: differentiation of nonprostatic neoplasms from metastatic prostate cancer. Am J Roentgenol. 2020;214(3):641\u20138. https:\/\/doi.org\/10.2214\/AJR.19.21894.","journal-title":"Am J Roentgenol"},{"issue":"11","key":"1546_CR33","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","volume":"5","author":"R Romero","year":"2024","unstructured":"Romero R, Chu T, Gonz\u00e1lez Robles TJ, Smith P, Xie Y, Kaur H, et al. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nat Cancer. 2024;5(11):1641\u201359. https:\/\/doi.org\/10.1038\/s43018-024-00838-6.","journal-title":"Nat Cancer"},{"issue":"12","key":"1546_CR34","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1007\/s00259-021-05501-1","volume":"48","author":"JH R\u00fcschoff","year":"2021","unstructured":"R\u00fcschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald AK, et al. What\u2019s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48(12):4042\u201353. https:\/\/doi.org\/10.1007\/s00259-021-05501-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1546_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322. PubMedPMID: 34161051;PubMed CentralPMCID:PMC8446332.","journal-title":"N Engl J Med"},{"issue":"7","key":"1546_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162907","volume":"8","author":"E Sayar","year":"2023","unstructured":"Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023;8(7):e162907. https:\/\/doi.org\/10.1172\/jci.insight.162907. PubMedPMID:36821396; PubMedCentralPMCID:PMC10132157.","journal-title":"JCI Insight"},{"key":"1546_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683793","volume":"11","author":"K Shen","year":"2021","unstructured":"Shen K, Liu B, Zhou X, Ji Y, Chen L, Wang Q, et al. The Evolving Role of 18F-FDG PET\/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer. Front Oncol. 2021;11:683793. https:\/\/doi.org\/10.3389\/fonc.2021.683793. PubMedPMID:34395251;PubMedCentralPMCID: PMC8358601.","journal-title":"Front Oncol"},{"issue":"12","key":"1546_CR38","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1158\/1078-0432.CCR-22-1305","volume":"29","author":"JM Sperger","year":"2023","unstructured":"Sperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, et al. Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. Clin Cancer Res. 2023;29(12):2324\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1305. PubMedPMID:36939530; PubMedCentralPMCID: PMC10261916.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1546_CR39","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1503747. PubMedPMID:26244877; PubMedCentralPMCID:PMC4562797.","journal-title":"N Engl J Med"},{"issue":"40","key":"1546_CR40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402741121","volume":"121","author":"Z Wang","year":"2024","unstructured":"Wang Z, Yu H, Bao W, Qu M, Wang Y, Zhang L, et al. Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics. Proc Natl Acad Sci U S A. 2024;121(40):e2402741121. https:\/\/doi.org\/10.1073\/pnas.2402741121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1546_CR41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.eururo.2024.09.005","volume":"86","author":"AB Weiner","year":"2024","unstructured":"Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, et al. Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-na\u00efve Prostate Cancer. Eur Urol. 2024;86(6):579\u201387. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.005.","journal-title":"Eur Urol"},{"issue":"7","key":"1546_CR42","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1007\/s00330-025-11358-x","volume":"35","author":"S Woo","year":"2025","unstructured":"Woo S, Becker AS, Leithner D, Mayerhoefer ME, Friedman KP, Tong A, et al. Discordance between prostate MRI and PSMA-PET\/CT: the next big challenge for primary prostate tumor assessment? Eur Radiol. 2025;35(7):4043\u201354. https:\/\/doi.org\/10.1007\/s00330-025-11358-x. PubMed PMID: 39853335.","journal-title":"Eur Radiol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01546-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:02:58Z","timestamp":1790168578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01546-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01546-w","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Ethics Committee of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine (Approval number: RA-2025\u2013897), with full compliance to the Declaration of Helsinki and institutional biosafety requirements.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. All clinical data and tissue samples used in this study were de-identified, and no identifiable personal information is included in this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"157"}}